Subsequent anticancer therapy (SAT) analysis from 3-year follow-up of the phase III TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in biliary tract cancer (BTC)

被引：0

作者：

Vogel, A. ^{[1
,2
]}

Oh, D-Y. ^{[3
,4
]}

He, A. R. ^{[5
]}

Qin, S. ^{[6
]}

Chen, L-T. ^{[7
]}

Okusaka, T. ^{[8
]}

Kim, J. W. ^{[9
]}

Suksombooncharoen, T. ^{[10
]}

Lee, M. A. ^{[11
]}

Kitano, M. ^{[12
]}

Burris, H. A. ^{[13
]}

Bouattour, M. ^{[14
]}

Tanasanvimon, S. ^{[15
]}

Zaucha, R. E. ^{[16
]}

Avallone, A. ^{[17
]}

Cundom, J. E. ^{[18
]}

Kuzko, A. ^{[19
]}

Wang, J. ^{[20
]}

Xynos, I. ^{[21
]}

Valle, J. W. ^{[22
]}

机构：

[1] Univ Hlth Network, Toronto Gen Hosp, Toronto, ON, Canada

[2] Princess Margaret Canc Ctr, Toronto, ON, Canada

[3] Seoul Natl Univ Hosp, Div Med Oncol, Dept Internal Med, Seoul, South Korea

[4] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea

[5] Georgetown Univ, Div Hematol & Oncol, Lombardi Comprehens Canc Ctr, Washington, DC USA

[6] Jinling Hosp, Canc Ctr Nanjing, Nanjing, Peoples R China

[7] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Ctr Canc Res, Kaohsiung, Taiwan

[8] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan

[9] Seoul Natl Univ, Med Oncol, Bundang Hosp, Seoul, South Korea

[10] Chiang Mai Univ, Fac Med, Dept Internal Med, Chiang Mai, Thailand

[11] Catholic Univ Korea, Seoul St Marys Hosp, Canc Res Inst, Coll Med, Seoul, South Korea

[12] Wakayama Med Univ, Dept Internal Med 2, Wakayama, Japan

[13] Sarah Cannon Res Inst, Drug Dev Dept, Nashville, TN USA

[14] Hop Beaujon, AP HP, Med Oncol, Paris, France

[15] Chulalongkorn Univ, King Chulalongkorn Mem Hosp, Fac Med, Thai Red Cross Soc, Bangkok, Thailand

[16] Med Univ Gdansk, Dept Oncol & Radiotherapy, Gdansk, Poland

[17] Ist Nazl Tumori IRCCS Fdn G Pascale, Abdominal Oncol Dept, Naples, Italy

[18] Inst Invest Metab, Med Oncol, Buenos Aires, DF, Argentina

[19] AstraZeneca, Late Oncol Stat, Warsaw, Poland

[20] AstraZeneca, Late Stage Dev, Oncol R&D, New York, NY USA

[21] AstraZeneca, Late Stage Dev, Oncol R&D, Cambridge, England

[22] Cholangiocarcinoma Fdn, Res, Herriman, UT USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.064

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

55P

引用

页码：S233 / S234

页数：2

共 50 条

[1] Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1)
Choe, Jung Wan
KOREAN JOURNAL OF GASTROENTEROLOGY, 2023, 82 (02): : 105 - 106
[2] Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC).
Vogel, Arndt
Chen, Li-Tzong
He, Aiwu Ruth
Kim, Jin Won
Chen, Ming-Huang
McNamara, Mairead Geraldine
Shimizu, Satoshi
Gillmore, Roopinder
Rey, Felipe
Kim, Hyosung
Xiong, Julia
Makowsky, Mallory
Rokutanda, Nana
Cohen, Gordon
Oh, Do-Youn
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[3] Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Okusaka, T.
Kitano, M.
Chen, M-H.
Chen, J-S.
Ostwal, V. S.
McNamara, M. G.
Breder, V.
Petrova, M.
Buchschacher, G.
Rokutanda, N.
Xiong, J.
Cohen, G.
Oh, D-Y.
ANNALS OF ONCOLOGY, 2022, 33 : S1471 - S1471
[4] Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in advanced biliary tract cancer (BTC)
Valle, J. W.
Qin, S.
Antonuzzo, L.
Tougeron, D.
Lee, C-K.
Tan, B. J.
Ikeda, M.
Guthrie, V.
McCoon, P.
Lee, Y. S.
Rokutanda, N.
Zotkiewicz, M.
Cohen, G.
Oh, D-Y.
ANNALS OF ONCOLOGY, 2022, 33 : S1457 - S1457
[5] Patient-reported outcomes for the phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.
Burris, Howard A., III
Okusaka, Takuji
Vogel, Arndt
Lee, Myung Ah
Takahashi, Hidenori
Breder, Valeriy Vladimirovich
Blanc, Jean-Frederic
Li, Junhe
Watras, Magdalena
Xiong, Julia
Abraham, Jayne
Patel, Nikunj
Wang, Julie
Rokutanda, Nana
Cohen, Gordon
Oh, Do-Youn
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[6] Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
Oh, D. Y.
He, A. R.
Qin, S.
Chen, L. T.
Okusaka, T.
Vogel, A.
Kim, J. W.
Suksombooncharoen, T.
Lee, M. A.
Kitano, M.
Burris, H. A.
Bouattour, M.
Tanasanvimon, S.
Zaucha, R. E.
Avallone, A.
Cundom, J. E.
Rokutanda, N.
Watras, M.
Cohen, G.
Valle, J. W.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S565 - S566
[7] Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
Oh, D-Y.
He, A. R.
Qin, S.
Chen, L-T.
Okusaka, T.
Vogel, A.
Kim, J. W.
Lee, T.
Lee, M. A.
Kitano, M.
Burris, H. A.
Bouattour, M.
Tanasanvimon, S.
Zaucha, R. E.
Avallone, A.
Cundom, J. E.
Rokutanda, N.
Zotkiewicz, M.
Cohen, G.
Valle, J. W.
ANNALS OF ONCOLOGY, 2022, 33 : S1462 - S1463
[8] Outcomes by antibiotic use in participants with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the Phase 3 TOPAZ-1 study
Pelzer, U.
He, A. R.
Tan, B.
Suksombooncharoen, T.
Takahashi, H.
Chen, M. -H.
Ostwal, V.
Oh, S. C.
Sezer, E.
Potemski, P.
Rau, K. -M.
Sirachainan, E.
Li, J.
Blanc, J. -F.
Cohen, G.
Zotkiewicz, M.
Rokutanda, N.
Oh, D. -Y.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 59 - 60
[9] Impact of mutation status on efficacy outcomes in TOPAZ-1: A Phase 3 study of Durvalumab (D) or Placebo (PBO) plus Gemcitabine and Cisplatin ( plus GC) in advanced Biliary Tract Cancer (BTC)
Vogel, A.
Valle, J.
Qin, S.
Antonuzo, L.
Tougeron, D.
Lee, C. -K.
Tan, B.
Ikeda, M.
Guthrie, V.
McCoon, P.
Lee, Y.
Rokutanda, N.
Watras, M.
Cohen, G.
Oh, D. -Y.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 63 - 64
[10] Impact of mutation status on efficacy outcomes in TOPAZ-1: A Phase 3 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in advanced biliary tract cancer (BTC)
Vogel, Arndt
Valle, Juan
Qin, Shukui
Antonuzzo, Lorenzo
Tougeron, David
Lee, Choongkun
Tan, Benjamin
Ikeda, Masafumi
Guthrie, Violeta
Mccoon, Patricia
Lee, Young
Rokutanda, Nana
Zotkiewicz, Magdalena
Cohen, Gordon
Oh, Do-Youn
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 68 - 68

← 1 2 3 4 5 →